The Function and Expression of ATP-Binding Cassette Transporters Proteins in the Alzheimer's Disease

Abstract

Despite many years of research, radical treatment of Alzheimer's disease (AD) has still not been found. Amyloid-β (Aβ) peptide is known to play an important role in the pathogenesis of this disease. AD is characterized by three main changes occurring in the central nervous system: (1) Aβ plaque accumulation that prevents synaptic communication, (2) the accumulation of hyperphosphorylated tau proteins that inhibit the transport of molecules inside neurons, and (3) neuronal cell loss of the limbic system. Mechanisms leading to Aβ accumulation in AD are excessive Aβ production as a result of mutations in amyloid precursor protein or genes, and impairment of clearance of Aβ due to changes in Aβ aggregation properties and/or Aβ removal processes. Human ATP-binding cassette (ABC) transporters are expressed in astrocyte, microglia, neuron, brain capillary endothelial cell, choroid plexus, choroid plexus epithelial cell, and ventricular ependymal cell. ABC transporters have essential detoxification and neuroprotective roles in the brain. The expression and functional changes in ABC transporters contribute to the accumulation of Aβ peptide. In conclusion, the review was aimed to summarize and highlight accumulated evidence in the literature focusing on the changing functions of human ABC transporter members, in AD pathogenesis and progression.

Keywords

ABC transporters / Alzheimer's diseases / amyloid-β / P-glycoprotein

References

[1] Jia Y, Wang N, Zhang Y, Xue D, Lou H, Liu X.Alteration in the function and expression of SLC and ABC transporters in the neurovascular unit in Alzheimer's disease and the clinical significance. Aging Dis 2020;11(02):390-404

[2] Seltzer B.Is long-term treatment of Alzheimer's disease with cholinesterase inhibitor therapy justified? Drugs Aging 2007;24(11):881-890

[3] Abuznait AH, Kaddoumi A.Role of ABC transporters in the pathogenesis of Alzheimer's disease. ACS Chem Neurosci 2012; 3(11):820-831

[4] Kim WS, Li H, Ruberu K, et al. Deletion of Abca7 increases cerebral amyloid-β accumulation in the J20 mouse model of Alzheimer's disease. J Neurosci 2013;33(10):4387-4394

[5] Hardy J, Selkoe DJ.The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297(5580):353-356

[6] Wolf A, Bauer B, Hartz AMS.ABC transporter and the Alzheimer's disease enigma. Front Psychiatry 2012;3:54

[7] Pahnke J, Langer O, Krohn M.Alzheimer's and ABC transporters- new opportunities for diagnostics and treatment. Neurobiol Dis 2014;72(Pt A):54-60

[8] Zlokovic BV.Clearing amyloid through the blood-brain barrier. J Neurochem 2004;89(04):807-811

[9] Allikmets R, Dean M.Cloning of novel ABC transporter genes. Methods Enzymol 1998;292:116-130

[10] Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001;11(07): 1156-1166

[11] Vasiliou V, Vasiliou K, Nebert DW.Human ATP-binding cassette (ABC) transporter family. Hum Genomics 2009;3(03):281-290

[12] Hartz AM, Bauer B.ABC transporters in the CNS - an inventory. Curr Pharm Biotechnol 2011;12(04):656-673

[13] Kim WS, Weickert CS, Garner B.Role of ATP-binding cassette transporters in brain lipid transport and neurological disease. J Neurochem 2008;104(05):1145-1166

[14] Gil-Martins E, Barbosa DJ, Silva V, Remião F, Silva R.Dysfunction of ABC transporters at the blood-brain barrier: role in neurological disorders. Pharmacol Ther 2020;213:107554

[15] Qosa H, Miller DS, Pasinelli P, Trotti D.Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders. Brain Res 2015;1628(Pt B):298-316

[16] Saunders NR, Habgood MD, Møllgård K, Dziegielewska KM. The biological significance of brain barrier mechanisms: help or hindrance in drug delivery to the central nervous system? F1000Res 2016;5:F1000 Faculty Rev 313

[17] de Boer AG, van der Sandt IC, Gaillard PJ. The role of drug transporters at the blood-brain barrier. Annu Rev Pharmacol Toxicol 2003;43:629-656

[18] Löscher W, Potschka H.Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2005;2(01): 86-98

[19] Bell RD, Zlokovic BV.Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 2009; 118(01):103-113

[20] Weiss N, Miller F, Cazaubon S, Couraud PO.The blood-brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta 2009;1788(04):842-857

[21] Anjard C, Loomis WFDictyostelium Sequencing Consortium. Evolutionary analyses of ABC transporters of Dictyostelium discoideum. Eukaryot Cell 2002;1(04):643-652

[22] Dean M, Hamon Y, Chimini G.The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 2001;42(07): 1007-1017

[23] Mack JT, Townsend DM, Beljanski V, Tew KD.The ABCA2 transporter: intracellular roles in trafficking and metabolism of LDLderived cholesterol and sterol-related compounds. Curr Drug Metab 2007;8(01):47-57

[24] Gosselet F, Candela P, Sevin E, Berezowski V, Cecchelli R, Fenart L.Transcriptional profiles of receptors and transporters involved in brain cholesterol homeostasis at the blood-brain barrier: use of an in vitro model. Brain Res 2009;1249:34-42

[25] Wahrle SE, Jiang H, Parsadanian M, et al.ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted ApoE. J Biol Chem 2004;279(39): 40987-40993

[26] Farrer LA, Cupples LA, Haines JL, et al; APOE and Alzheimer Disease Meta Analysis Consortium. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. JAMA 1997;278(16): 1349-1356

[27] Holtzman DM, Fagan AM, Mackey B, et al.Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol 2000;47(06):739-747

[28] Wahrle SE, Jiang H, Parsadanian M, et al.Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mousemodel of Alzheimer disease. J Biol Chem 2005;280(52):43236-43242

[29] Broccardo C, Nieoullon V, Amin R, et al.ABCA2 is a marker of neural progenitors and neuronal subsets in the adult rodent brain. J Neurochem 2006;97(02):345-355

[30] Shawahna R, Uchida Y, Declèves X, et al.Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol Pharm 2011;8(04):1332-1341

[31] Pahnke J,Wolkenhauer O, KrohnM,Walker LC. Clinico-pathologic function of cerebral ABC transporters - implications for the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 2008;5(04):396-405

[32] Chen ZJ, Vulevic B, Ile KE, et al.Association of ABCA2 expression with determinants of Alzheimer's disease. FASEB J 2004;18(10): 1129-1131

[33] Michaki V, Guix FX, Vennekens K, et al.Down-regulation of the ATP-binding cassette transporter 2 (Abca2) reduces amyloid-β production by altering Nicastrin maturation and intracellular localization. J Biol Chem 2012;287(02):1100-1111

[34] Fu Y, Hsiao JH, Paxinos G, Halliday GM, Kim WS.ABCA5 regulates amyloid-β peptide production and is associated with Alzheimer's disease neuropathology. J Alzheimers Dis 2015;43(03):857-869

[35] Quazi F, Molday RS.Differential phospholipid substrates and directional transport by ATP-binding cassette proteins ABCA1, ABCA7, and ABCA4 and disease-causing mutants. J Biol Chem 2013;288(48):34414-34426

[36] Iwamoto N, Abe-Dohmae S, Sato R, Yokoyama S.ABCA7 expression is regulated by cellular cholesterol through the SREBP2 pathway and associated with phagocytosis. J Lipid Res 2006;47(09):1915-1927

[37] Cascorbi I, Flüh C, Remmler C, et al.Association of ATP-binding cassette transporter variants with the risk of Alzheimer's disease. Pharmacogenomics 2013;14(05):485-494

[38] Zhao QF, Yu JT, Tan MS, Tan L.ABCA7 in Alzheimer's disease. Mol Neurobiol 2015;51(03):1008-1016

[39] Chan SL, Kim WS, Kwok JB, et al.ATP-binding cassette transporter A7 regulates processing of amyloid precursor protein in vitro. J Neurochem 2008;106(02):793-804

[40] Bamji-Mirza M, Li Y, Najem D, et al.Genetic variations in ABCA7 can increase secreted levels of amyloid-40 and amyloid-42 peptides and ABCA7 transcription in cell culturemodels. J Alzheimers Dis 2016;53(03):875-892

[41] Vasquez JB, Fardo DW, Estus S.ABCA7 expression is associated with Alzheimer's disease polymorphism and disease status. Neurosci Lett 2013;556:58-62

[42] Begley DJ.ABC transporters and the blood-brain barrier. Curr Pharm Des 2004;10(12):1295-1312

[43] Chai AB, Leung GKF, Callaghan R, Gelissen IC.P-glycoprotein: a role in the export of amyloid-β in Alzheimer's disease? FEBS J 2020;287(04):612-625

[44] Cirrito JR, Deane R, Fagan AM, et al.P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer diseasemouse model. J Clin Invest 2005;115(11):3285-3290

[45] Hartz AM, Miller DS, Bauer B.Restoring blood-brain barrier Pglycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease. Mol Pharmacol 2010;77(05):715-723

[46] Rajagopal A, Simon SM.Subcellular localization and activity of multidrug resistance proteins. Mol Biol Cell 2003;14(08): 3389-3399

[47] Donovan MH, Yazdani U, Norris RD, Games D, German DC, Eisch AJ.Decreased adult hippocampal neurogenesis in the PDAPP mouse model of Alzheimer's disease. J Comp Neurol 2006;495(01):70-83

[48] Vogelgesang S, Warzok RW, Cascorbi I, et al.The role of Pglycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. Curr Alzheimer Res 2004;1(02):121-125

[49] van Assema DM, Lubberink M, Boellaard R, et al. P-glycoprotein function at the blood-brain barrier: effects of age and gender.Mol Imaging Biol 2012;14(06):771-776

[50] Wang YJ, Zhou HD, Zhou XF.Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives. Drug Discov Today 2006;11(19-20):931-938

[51] Damar U, Gersner R, Johnstone JT, Schachter S, Rotenberg A.Huperzine A as a neuroprotective and antiepileptic drug: a review of preclinical research. Expert Rev Neurother 2016;16(06): 671-680

[52] Krohn M, Lange C, Hofrichter J, et al.Cerebral amyloid-β proteostasis is regulated by the membrane transport protein ABCC1 in mice. J Clin Invest 2011;121(10):3924-3931

[53] Soontornmalai A, Vlaming ML, Fritschy JM.Differential, strainspecific cellular and subcellular distribution of multidrug transporters in murine choroid plexus and blood-brain barrier. Neuroscience 2006;138(01):159-169

[54] Roberts LM, Black DS, Raman C, et al.Subcellular localization of transporters along the rat blood-brain barrier and blood-cerebral- spinal fluid barrier by in vivo biotinylation. Neuroscience 2008;155(02):423-438

[55] Warren MS, Zerangue N, Woodford K, et al.Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human. Pharmacol Res 2009;59(06):404-413

[56] Sodani K, Patel A, Kathawala RJ, Chen ZS.Multidrug resistance associated proteins in multidrug resistance. Chin J Cancer 2012; 31(02):58-72

[57] Tansley GH, Burgess BL, Bryan MT, et al.The cholesterol transporter ABCG1 modulates the subcellular distribution and proteolytic processing of beta-amyloid precursor protein. J Lipid Res 2007;48(05):1022-1034

[58] Doyle LA, Yang W, Abruzzo LV, et al.A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 1998;95(26):15665-15670

[59] Wijesuriya HC, Bullock JY, Faull RL, Hladky SB, Barrand MA.ABC efflux transporters in brain vasculature of Alzheimer's subjects. Brain Res 2010;1358:228-238

[60] Xiong H, Callaghan D, Jones A, et al.ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1-40) peptides. J Neurosci 2009;29(17):5463-5475

[61] Zeng Y, Callaghan D, Xiong H, Yang Z, Huang P, Zhang W.Abcg2 deficiency augments oxidative stress and cognitive deficits in Tg- SwDI transgenic mice. J Neurochem 2012;122(02):456-469

[62] Shen S, Callaghan D, Juzwik C, Xiong H, Huang P, Zhang W.ABCG2 reduces ROS-mediated toxicity and inflammation: a potential role in Alzheimer's disease. J Neurochem 2010;114(06): 1590-1604

[63] Do TM, Noel-Hudson MS, Ribes S, et al.ABCG2- and ABCG4- mediated efflux of amyloid-β peptide 1-40 at the mouse bloodbrain barrier. J Alzheimers Dis 2012;30(01):155-166

RIGHTS & PERMISSIONS

2021 Global Medical Genetics